Expand IMNN Menu
IMNN MENU

IMNN Latest Press Releases

-- March 25, 2026 --

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer Globe Newswire 8:05 AM

-- March 24, 2026 --

IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 Globe Newswire 8:00 AM

-- February 5, 2026 --

IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY Globe Newswire 8:05 AM

-- December 30, 2025 --

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules Globe Newswire 8:30 AM

-- December 29, 2025 --

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 Globe Newswire 11:10 AM

-- November 13, 2025 --

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update Globe Newswire 7:45 AM

-- November 10, 2025 --

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer Globe Newswire 1:30 PM
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer Globe Newswire 7:30 AM

-- November 7, 2025 --

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment Globe Newswire 8:05 AM

-- November 6, 2025 --

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025 Globe Newswire 8:05 AM

-- November 4, 2025 --

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer Globe Newswire 8:05 AM
Market Data Delayed 15 Minutes